Canadian Journal of Health Technologies, 2023 CADTH recommends that Ferriprox should be reimbursed by public drug plans for the treatment of patients with transfusional iron overload due to sickle cell disease (SCD) or other anemias if certain conditions are met.
Deferiprone Ferriprox, Chiesi Canada
semanticscholar +2 more sources
Metabolic activation of deferiprone mediated by CYP2A6
Xenobiotica, 2021 Deferiprone (DFP) is a metal chelating agent generally used to treat patients with thalassaemia, due to iron overload in clinical settings. Studies have revealed that long-term use of DFP can induce hepatotoxicity, however, mechanisms of its toxic action
Xiaojiao Zheng +5 more
semanticscholar +4 more sources
Combined therapy with deferiprone and desferrioxamine [PDF]
British Journal of Haematology, 1998 In a proportion of transfusion‐dependent patients iron chelation with daily doses of deferiprone of 75 mg/kg body weight (b.w.) is inadequate. The effects on iron status of increasing the daily oral dose of deferiprone and/or combining deferiprone therapy with subcutaneous infusions of desferrioxamine have been studied in 13 transfusion‐dependent ...
Wonke, Wright, Hoffbrand
openalex +4 more sources
Salmonella Typhimurium and Pseudomonas aeruginosa Respond Differently to the Fe Chelator Deferiprone and to Some Novel Deferiprone Derivatives [PDF]
International Journal of Molecular Sciences, 2021 The ability to obtain Fe is critical for pathogens to multiply in their host. For this reason, there is significant interest in the identification of compounds that might interfere with Fe management in bacteria.
Serena Ammendola +8 more
semanticscholar +5 more sources
Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major [PDF]
, 2013 Transfusion and iron chelation treatment have significantly reduced morbidity and improved survival of patients with thalassemia major. However, cardiac disease continues to be the most common cause of death.
Aldo Filosa +18 more
openalex +4 more sources
Beyond Simple Grinding: Methylammonium Chloride Promotes Sustainable, Cylinder-Free Mechanochemical Synthesis of Deferiprone. [PDF]
ChemSusChemDeferiprone is synthesized under solvent‐free mechanochemical conditions using ball milling. Methylammonium chloride and KOH enable efficient substitution of the oxygen atom in the maltol scaffold with a methylamine moiety, avoiding the limitations of methylamine solutions.
Basoccu F +6 more
europepmc +2 more sources
Deferiprone or fatal iron toxic effects? [PDF]
The Lancet, 2001 Kontoghiorghes Gj +3 more
openalex +5 more sources
Bismuth coordination networks containing deferiprone: synthesis, characterisation, stability and antibacterial activity [PDF]
, 2015 A series of bismuth–dicarboxylate–deferiprone coordination networks have been prepared and structurally characterised. The new compounds have been demonstrated to release the iron overload drug deferiprone on treatment with PBS and have also been shown ...
Andrew D. Burrows +6 more
openalex +4 more sources
MRI prospective survey on cardiac and hepatic iron in transfusion-dependent thalassemia intermedia patients treated with desferrioxamine, deferiprone and deferasirox [PDF]
, 2015 Antonella Meloni +9 more
openalex +3 more sources
The Effectiveness of Deferiprone in Thalassemia [PDF]
Blood, 1997 To the Editor: In a note added in proof to their excellent review on iron chelation, Olivieri and Brittenham[1][1] updated your readers on two abstracts recently presented by them to suggest that deferiprone may not provide adequate control of body iron in a substantial proportion of patients ...
Graham D. Sher +3 more
openaire +4 more sources